InflaRx Reports Narrower Nine-Month Loss Through September 2026
Management cited lower research and development spending as the driver.
Related stories
Burckhardt Compression Reports H1 Order Intake Growth, Confirms Guidance
Order intake rose 5.4% in the first half of fiscal 2026/27, exceeding analyst expectations. Sales declined amid backlog and delivery phasing; adjusted EBIT margin was 12.8%. The co
M impact | EARNINGS | Nov 03, 2026, 04:33 PM UTC
PS International Group Reports 1H Revenue of $26.5M
M impact | EARNINGS | Nov 03, 2026, 04:32 PM UTC
Teva Raises 2026 Revenue Forecast After Third-Quarter Profit Beat
Teva reported higher-than-expected third-quarter profit, with branded-drug sales offsetting declines in generics, and raised its 2026 forecasts.
M impact | EARNINGS | Nov 03, 2026, 04:32 PM UTC
PS International Group Announces First-Half 2026 Results
PS International Group announced unaudited financial results for the first half of 2026.
M impact | EARNINGS | Nov 03, 2026, 04:32 PM UTC
Peoples Bancorp of North Carolina Reports Q3 2026 Net Income of $5.7 Million
Third-quarter net income rose 55.1% year over year to $5.7 million. Net interest income increased 10.4% to $16.7 million, and diluted EPS rose to $1.05 from $0.67.
M impact | EARNINGS | Nov 03, 2026, 04:31 PM UTC
Reklaim Swings to Q3 Net Income; Shares Rise 40%
Reklaim reported third-quarter net income of CA$1.3.
M impact | EARNINGS | Nov 03, 2026, 04:28 PM UTC